Stem Cell and Exosome Clinics: The Claims the FDA Treats as Unapproved Drugs

If your clinic markets stem cell, exosome, umbilical cord, amniotic, or PRP products to treat named diseases, you are operating in one of the FDA’s most active enforcement areas. The short version is this. Most of these products are unapproved biologics, not approved drugs, and the moment your website says one of them treats arthritis, autoimmune disease, neuropathy, or anything else with a name, you have made a drug claim for a product the FDA has not cleared. That is what draws warning letters. This post walks through the three triggers that show up again and again, and the safer language that keeps your copy honest without overclaiming.

This is a screening and educational tool, not legal or regulatory clearance. Your clinic’s own physician and counsel are the final gate on every claim you publish.

TL;DR

• Marketing stem cell, exosome, cord blood, amniotic, or PRP products to treat a named disease turns them into unapproved new drugs in the FDA’s eyes, and that is the single most common trigger in this space.
• Human cells and tissues are regulated under 21 CFR Part 1271, and the safe harbor only holds if the product is minimally manipulated and used for a homologous (same basic function) purpose. Step outside that and you need approval you almost certainly do not have.
• Regeneration, repair, and “restore your body” claims are substantiation claims, and the FTC expects competent and reliable scientific evidence behind every one of them.
• Recent warning letters to Blue Horizon International, BioXtek, and Lux Therapeutics show the FDA citing exactly these patterns: unapproved biologics and Part 1271 violations.
• The safer move is to describe the procedure, not promise the disease outcome, and to run your copy through a screen before it goes live.

Pattern 1: treating a named disease with an unapproved biologic

This is the trigger behind most enforcement in regenerative medicine. Under Section 201(g) of the Federal Food, Drug, and Cosmetic Act, a product becomes a “drug” when it is intended to diagnose, cure, mitigate, treat, or prevent disease [2]. Intent is read straight off your marketing. If your page says an umbilical cord or exosome product treats osteoarthritis, COPD, Parkinson’s, or autoimmune conditions, you have stated drug intent for a biologic the FDA has not approved.

The FDA’s May 2026 action against Blue Horizon International, LLC is a clean example. CBER cited the company over marketing of unapproved umbilical cord blood-derived stem cell products. You can read the breakdown in the Blue Horizon International warning letter. The agency has also published a consumer-facing warning specifically about stem cell therapies marketed beyond their approved uses [5].

Safer phrasing is about scope. Instead of “our stem cell therapy treats knee arthritis,” describe what the procedure is and what it involves, and keep disease-outcome promises off the page entirely unless you hold the approval to back them. Naming a disease as the thing your product fixes is the line.

Pattern 2: stepping outside the Part 1271 safe harbor

Human cells, tissues, and cellular and tissue-based products (HCT/Ps) are regulated under 21 CFR Part 1271. There is a regulatory lane that lets some of these products be used without premarket approval, but only when two conditions hold. The product must be minimally manipulated, and it must be used for a homologous purpose, meaning the same basic function it performs in the donor. Process the tissue beyond minimal manipulation, or market it for a function it does not naturally serve, and you fall out of the safe harbor and into “unapproved product” territory.

Two recent letters show how the FDA frames this. In November 2025, Lux Therapeutics LLC (doing business as Ponya Therapeutics) was cited for significant violations of 21 CFR Part 1271 governing HCT/Ps. The detail is in the Lux Therapeutics warning letter. In December 2025, BioXtek LLC was cited after inspection over human amniotic membrane-derived products (its Sanoplast ECM and DG lines). These are not marketing-only cases, they reach into how the product is processed and what it is sold to do.

You usually cannot fix a Part 1271 problem with wording alone, because the regulation turns on the product and the process, not just the page. But your marketing should never imply a use that pushes an amniotic or cord-derived product past homologous use. If your supplier’s product is positioned for injection into joints or systemic disease, that is a manufacturing-and-approval question to raise with your physician and counsel before a single claim goes up.

Pattern 3: unsubstantiated regeneration and repair claims

Even where a procedure is lawful, the claims around it still have to be supported. “Regenerate damaged tissue,” “repair your joints,” and “restore your body’s natural healing” are all health claims, and the FTC’s Health Products Compliance Guidance expects competent and reliable scientific evidence behind them [1]. The FTC enforces this under its Section 5 authority over deceptive advertising [4], and the FDA issues warning letters for unsupported and unapproved claims as a matter of routine [3].

The trap here is enthusiasm. A clinic that genuinely believes in its results writes copy in the language of certainty, “rebuilds cartilage,” “reverses degeneration,” when the published evidence does not carry that weight. The safer version describes the mechanism in measured terms and avoids promising an anatomical outcome you cannot prove. “A procedure some patients pursue as part of a broader plan” is defensible. “Regrows your knee” is not.

How to check your regenerative-medicine copy

Before any stem cell, exosome, PRP, or amniotic page goes live, run it through the free Claim Checker. It screens your wording against the patterns above: named-disease drug claims, language that implies non-homologous use, and regeneration or repair promises that need substantiation. It flags the risky phrasing and suggests safer alternatives so your physician has a cleaner draft to attest.

The Claim Checker is a screen, not a sign-off. It catches the common triggers fast, but your clinic’s physician and counsel remain the final gate. To see how the FDA has actually worded its actions in this vertical, browse the stem cell and regenerative medicine warning letters in the Atlas. Reading the agency’s own language is the fastest way to calibrate your own. For the broader picture of what language draws letters across health verticals, start with the pillar on marketing claims that trigger FDA warning letters.

Frequently asked questions

Can I say my stem cell or exosome therapy treats arthritis if patients have improved?

No, not safely. The moment you tie the product to treating a named disease, you have stated drug intent under Section 201(g) of the FD&C Act, and for an unapproved biologic that is the most common warning-letter trigger in this space. Anecdotal patient improvement does not change the regulatory status of the product. If you want to publish outcomes, that is a conversation to have with your physician and counsel about what evidence you hold and how it can be described, not a green light to name the disease your therapy “treats.”

What is the 21 CFR Part 1271 safe harbor, and why does it matter for amniotic and cord products?

Part 1271 governs human cells, tissues, and cellular and tissue-based products. There is a narrow lane that allows some of these products to be used without premarket approval, but only when they are minimally manipulated and used for a homologous purpose, meaning the same basic function the tissue performs in the donor. Amniotic and cord-derived products marketed for joint injection or systemic disease often fall outside that lane, which is exactly what the FDA cited in the BioXtek and Lux Therapeutics actions. Because the issue turns on how the product is processed and used, wording alone usually cannot fix it.

Is PRP regulated the same way as stem cell products?

PRP (platelet-rich plasma) sits in a different and often less restrictive category than stem cell or exosome products, but the claims around it are policed by the same rules. If you market PRP as a treatment for a named disease, or promise it regenerates or repairs tissue without competent and reliable scientific evidence, you can still draw an FTC or FDA action. The regulatory category of the product and the claims you make about it are two separate compliance questions, and you have to clear both.

Does running my page through the Claim Checker make it FDA-compliant?

No. The Claim Checker is a screening and educational tool. It catches the common triggers (named-disease drug claims, non-homologous-use language, unsubstantiated regeneration claims) and suggests safer phrasing, but it does not grant regulatory clearance and it does not replace review. Your clinic’s own physician and counsel are the final gate on everything you publish.

Citations

1. Federal Trade Commission. Health Products Compliance Guidance. December 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance . Accessed June 8, 2026.
2. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 201(g) (definition of “drug”). https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act . Accessed June 8, 2026.
3. U.S. Food and Drug Administration. Warning Letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters . Accessed June 8, 2026.
4. Federal Trade Commission. Enforcement Authority (Section 5). https://www.ftc.gov/about-ftc/mission/enforcement-authority . Accessed June 8, 2026.
5. U.S. Food and Drug Administration. FDA Warns About Stem Cell Therapies. https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies . Accessed June 8, 2026.